Perseus announced after trading ended on the 29th that it had signed a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. aimed at creating novel antibody drugs. The agreement is intended to develop novel treatments in specific disease areas, using the company’s antibody technology to create new antibody drugs.
Perseus announced after trading ended that it had signed a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. The agreement is intended to develop novel treatments for specific disease areas. The two companies plan to use antibody technology to create novel antibody drugs.
The agreement is expected to have only a minor impact on current-year results, and no basis has been presented for assuming an excessive direct impact on financial performance. The text does not disclose any specific figures or period.